Request Trial
8 December 2016Americas

CRISPR dispute likely to continue in federal courts

Following the CRISPR/Cas9 patent hearing on December 6 between The Broad Institute and University of California, Berkeley (UCB), it is very unlikely that the case will end at the US Patent and Trademark Office (USPTO), according to one lawyer.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
SCOTUS flooded with briefs calling for reversal of ‘skinny label’ ruling
26 February 2026   As the US Supreme Court prepares to hear arguments in the Hikma and Amarin dispute, the case has drawn a broad coalition of industry support—including the US government and a co-author of the Hatch-Waxman Act itself.
Americas
Eli Lilly escapes $278m payout in biotech licensing dispute
26 February 2026   In a decision with implications for biotechnology licensing and pharmaceutical manufacturing, the Ninth Circuit has rejected a ‘sweeping’ royalty trigger from a lower court.
Americas
Novo battles for GLP-1 leadership with fresh lawsuit and slashed prices
25 February 2026   The Danish company is contending with fierce competition, a clinical trial setback and a UK boost to its main rival, while making new moves to enforce its weight-loss-drug IP.


Editor's picks

Eli Lilly escapes $278m payout in biotech licensing dispute
Americas
Eli Lilly escapes $278m payout in biotech licensing dispute
26 February 2026

Editor's picks

Americas
Eli Lilly escapes $278m payout in biotech licensing dispute
26 February 2026

More features

SCOTUS flooded with briefs calling for reversal of ‘skinny label’ ruling
Eli Lilly escapes $278m payout in biotech licensing dispute
Novo battles for GLP-1 leadership with fresh lawsuit and slashed prices
Wiggin’s new litigation partner deepens ‘technically complex’ offer
Could everyday hospital equipment be the next defence against counterfeit medicines?
BioNTech fires shots at Moderna's next-generation vaccine
Mintz gains ex-Winston & Strawn partner and ITC expert
Abbott unit defends European protection for heart valve ‘cuff’ design